DDInter624 DDInter1377
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
Efavirenz {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Paclitaxel
Efavirenz {u} (Compound) downregulates {v} (Gene) RFC2
RFC2 {u} (Gene) is downregulated by {v} (Compound) Paclitaxel
Efavirenz {u} (Compound) causes {v} (Side Effect) Dry mouth
Dry mouth {u} (Side Effect) is caused by {v} (Compound) Paclitaxel
Efavirenz {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Cabazitaxel
Cabazitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Paclitaxel
Efavirenz {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Paclitaxel
Efavirenz {u} (Compound) downregulates {v} (Gene) RFC2
RFC2 {u} (Gene) is downregulated by {v} (Compound) Docetaxel
Docetaxel {u} (Compound) resembles {v} (Compound) Paclitaxel
Efavirenz {u} (Compound) downregulates {v} (Gene) OXA1L
OXA1L {u} (Gene) is regulated by {v} (Gene) ABCC10
ABCC10 {u} (Gene) is bound by {v} (Compound) Paclitaxel
Efavirenz {u} (Compound) causes {v} (Side Effect) Dry mouth
Dry mouth {u} (Side Effect) is caused by {v} (Compound) Cabazitaxel
Cabazitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Paclitaxel
Efavirenz {u} (Compound) causes {v} (Side Effect) Skin discolouration
Skin discolouration {u} (Side Effect) is caused by {v} (Compound) Sparfloxacin
Sparfloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Paclitaxel
Efavirenz {u} (Compound) causes {v} (Side Effect) Necrosis
Necrosis {u} (Side Effect) is caused by {v} (Compound) Docetaxel
Docetaxel {u} (Compound) resembles {v} (Compound) Paclitaxel
Efavirenz (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Paclitaxel (Compound)
Efavirenz (Compound) downregulates RFC2 (Gene) and RFC2 (Gene) is downregulated by Paclitaxel (Compound)
Efavirenz (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Paclitaxel (Compound)
Efavirenz (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cabazitaxel (Compound) and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Efavirenz (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Paclitaxel
Efavirenz (Compound) downregulates RFC2 (Gene) and RFC2 (Gene) is downregulated by Docetaxel (Compound) and Docetaxel (Compound) resembles Paclitaxel (Compound)
Efavirenz (Compound) downregulates OXA1L (Gene) and OXA1L (Gene) is regulated by ABCC10 (Gene) and ABCC10 (Gene) is bound by Paclitaxel (Compound)
Efavirenz (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Cabazitaxel (Compound) and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Efavirenz (Compound) causes Skin discolouration (Side Effect) and Skin discolouration (Side Effect) is caused by Sparfloxacin (Compound) and Sparfloxacin may cause a minor interaction that can limit clinical effects when taken with Paclitaxel
Efavirenz (Compound) causes Necrosis (Side Effect) and Necrosis (Side Effect) is caused by Docetaxel (Compound) and Docetaxel (Compound) resembles Paclitaxel (Compound)